Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

In this phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than placebo with respect to resolution of MASH without worsening of fibrosis.

​   The New England Journal of Medicine: Search Results in Gastroenterology